Global Ophthalmology Drugs Market Report 2019 with Profiles of Novartis, F. Hoffmann-La Roche, Allergan, Valeant Pharmaceuticals, Bayer -

DUBLIN--()--The "Ophthalmology Drugs Global Market Report 2019" report has been added to's offering.

Global Ophthalmology Drugs Market Report 2019 provides the strategists, marketers and senior management with the critical information they need to assess the global ophthalmology drugs market.

Where is the largest and fastest growing market for the ophthalmology drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Ophthalmology Drugs market global report answers all these questions and many more.

The ophthalmology drugs market consists of sales of ophthalmology drugs and related services by entities (organizations, sole traders and partnerships) that produce ophthalmology drugs to treat eye related diseases. This industry includes establishments that produce antiglaucoma drugs used to treat glaucoma diseases, anti- inflammatory and tear stimulating drugs under dry eye medications drugs, and other drugs for treating retinal disorders and allergies.

Asia Pacific was the largest region in the global ophthalmology drugs market, accounting for 36% of the market in 2018. North America was the second largest region accounting for 27% of the global ophthalmology drugs market. Africa was the smallest region in the global ophthalmology drugs market.

Drug manufacturers are developing new class of compounds called Rho-kinase inhibitors for the treatment of glaucoma. Rho-kinase pathway is an integral part of cellular functions such as contraction of vascular smooth muscle cells, organization of the actin cytoskeleton, cell adhesion and motility and gene expression.

These inhibitors are different from widely used prostaglandin analogs because they target the outflow through trabecular meshwork rather than the uveoscleral outflow. Rho-kinase inhibitors have proved to decrease intraocular pressure by 25% to 30% with duration of action of 10 to 12 hours, which is more effective than the previous generation of drugs for this condition.

Major Rho-kinase inhibitors being developed include ATS907, ATS8535, AR-12286, AR-13324, AMA0076 and BOL-303259-X.

Key Topics Covered:

1. Executive Summary

2. Report Structure

3. Ophthalmology Drugs Market Characteristics

3.1. Market Definition

3.2. Key Segmentations

4. Ophthalmology Drugs Market Product Analysis

4.1. Leading Products/ Services

4.2. Key Features and Differentiators

4.3. Development Products

5. Ophthalmology Drugs Market Supply Chain

5.1. Supply Chain

5.2. Distribution

5.3. End Customers

6. Ophthalmology Drugs Market Customer Information

6.1. Customer Preferences

6.2. End Use Market Size and Growth

7. Ophthalmology Drugs Market Trends And Strategies

8. Ophthalmology Drugs Market Size And Growth

8.1. Market Size

8.2. Historic Market Growth, Value ($ Billion)

8.2.1. Drivers Of The Market

8.2.2. Restraints On The Market

8.3. Forecast Market Growth, Value ($ Billion)

8.3.1. Drivers Of The Market

8.3.2. Restraints On The Market

9. Ophthalmology Drugs Market Regional Analysis

9.1. Global Ophthalmology Drugs Market, 2018, By Region, Value ($ Billion)

9.2. Global Ophthalmology Drugs Market, 2014 - 2022, Historic And Forecast, By Region

9.3. Global Ophthalmology Drugs Market, Growth And Market Share Comparison, By Region

10. Ophthalmology Drugs Market Segmentation

10.1. Global Ophthalmology Drugs Market, Segmentation By Type, 2014 - 2022, Value ($ Billion)

10.1.1. Antiglaucoma Drugs

10.1.2. Dry Eye Medication

10.1.3. Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy)

11. Ophthalmology Drugs Market Metrics

11.1. Ophthalmology Drugs Market Size, Percentage Of GDP, 2014 - 2022, Global

11.2. Per Capita Average Ophthalmology Drugs Market Expenditure, 2014 - 2022, Global

Companies Mentioned

  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Allergan Plc
  • Valeant Pharmaceuticals Intl Inc
  • Bayer AG

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Optical Disorders Drugs

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Optical Disorders Drugs